PT-141 , in contrast, does not rely on vascular pathways
Specific mutations in genes controlling GLP-1 receptor signaling, appetite regulation, and fat metabolism influence baseline sensitivity to these drugs
Front Physiol 2013
GLP-1Rs are expressed in the pancreas, intestinal intraepithelial lymphocytes, myocardium, adipose tissue, kidney, liver, blood vessels, lungs and in the CNS.2,3 Although GLP-1 is known for its incretin effect, which it shares with glucose-dependent insulinotropic peptide (GIP), the intake-regulating action, essential for its efficacy against obesity, occurs through its interaction with receptors located in the CNS.1,5 The GLP-1 peptide can reach the central nervous system (CNS) via peripheral vagal afferents, which transmit its action through the nodose ganglion to the nucleus tactus solitarius (NTS)